Clinical Trial: The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study
Brief Summary: A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.
Detailed Summary: Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study
Sponsor: Wills Eye
Current Primary Outcome: Safety of Intravitreal Aflibercept Injection [ Time Frame: 6 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Change in Vision Based on Letter Score [ Time Frame: 6 months ]
Original Secondary Outcome: Change in Vision Based on Letter Score [ Time Frame: 6 months ]
- Mean change from baseline in best-corrected ETDRS (Early Treatment of Diabetic Retinopathy Study) letter score
- Percentage of eyes with 20/40 or better vision
- Percentage of eyes with ≥ 15-letter gain from baseline
- Percentage of eyes with < 15-letter loss from baseline
Information By: Wills Eye
Dates:
Date Received: October 16, 2012
Date Started: October 2012
Date Completion:
Last Updated: February 22, 2017
Last Verified: February 2017